Biotech · Private company · Salt Lake City, UT, US
Curza Inc
Track this companyFree. Adds Curza Inc to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards7
- New oral antibiotics focused on treating MDR Gram-negative infectionsFiscal year 2026 · $1MNIH RePORTER 5R44AI186898-03 · fetched Nov 12, 2026
- A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant PathogensFiscal year 2025 · $858.4KNIH RePORTER 5R44AI170297-03 · fetched Nov 12, 2026
- A new class of antibiotic to address Antimicrobial ResistanceFiscal year 2025 · $1MNIH RePORTER 5R44AI184155-02 · fetched Nov 12, 2026
- New oral antibiotics focused on treating MDR Gram-negative infectionsFiscal year 2025 · $1MNIH RePORTER 5R44AI186898-02 · fetched Nov 12, 2026
- A new class of antibiotic to address Antimicrobial ResistanceFiscal year 2024 · $1MNIH RePORTER 1R44AI184155-01 · fetched Nov 12, 2026
- New oral antibiotics focused on treating MDR Gram-negative infectionsFiscal year 2024 · $1MNIH RePORTER 1R44AI186898-01 · fetched Nov 12, 2026
- A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant PathogensFiscal year 2024 · $1MNIH RePORTER 5R44AI170297-02 · fetched Nov 12, 2026